The United Laboratories International Holdings (HK:3933) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The United Laboratories International Holdings Limited has announced the acceptance of their Insulin Degludec Injection by China National Medical Products Administration, marking a significant stride in diabetes treatment with their new generation long-acting basal insulin analog. The company is further developing a range of diabetes-related products, emphasizing its commitment to innovation and value creation in the biopharmaceutical industry for its shareholders.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.
